MARQUEE collapses on tivantinib in NSCLC but other uses offer hope
This article was originally published in Scrip
Executive Summary
ArQule and Daiichi Sankyo have not completely lost hope for the c-Met inhibitor tivantinib (ARQ 197), but they have given up on treating patients who have non-small cell lung cancer (NSCLC) after the drug failed in the Phase III MARQUEE study to achieve statistical significance in the pivotal trial's primary endpoint of improvement in overall survival (OS).
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.